Phytocannabinoid Extracts for Hormone-Insensitive Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for hormone-insensitive prostate cancer, are ineffective in controlling tumor growth, and existing therapies fail to address the metastatic and proliferative aspects of various cancer types effectively.
Innovation Solution
The use of cannabis plant extracts comprising a phytocannabinoid-containing component, which constitutes at least 50% of the extract, along with a non-phytocannabinoid containing component including monoterpene and sesquiterpene fractions, is proposed for the treatment of cancer, specifically targeting hormone-sensitive and hormone-insensitive prostate cancer, as well as other types like breast, colon, and glioma, by inhibiting cell proliferation and inducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, hormone treatment, radiotherapy) are used, then tumor growth is initially controlled, but treatment effectiveness is lost over time as cancer becomes hormone-insensitive and develops resistance
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapeutic agents to phytocannabinoids (THC, CBD, CBC) and their derivatives, which act through a different mechanism (cannabinoid receptor CB1 and CB2 pathways) to overcome hormone-insensitivity and treatment resistance, thereby restoring and maintaining treatment effectiveness over extended periods
Solution Approach 2:
The invention uses composite cannabis plant extracts containing multiple phytocannabinoids (THC, CBD, CBC) along with non-phytocannabinoid components including monoterpene and sesquiterpene fractions, creating a multi-component therapeutic formulation that addresses treatment resistance through synergistic effects
2Quantity of substance
If isolated phytocannabinoids are used, then the active therapeutic component is concentrated, but the complexity of isolation and purification processes increases
Solution Approach 1:
The patent extracts and isolates specific phytocannabinoids (THC, CBD, CBC) from cannabis plant material using standard extraction techniques, separating the active therapeutic components from the plant matrix while maintaining their pharmacological activity, thereby concentrating the therapeutic agent without requiring overly complex processing
Solution Approach 2:
The invention utilizes the entire cannabis plant or its extracts as a multi-functional source that provides both isolated phytocannabinoids and composite formulations, allowing the same source material to serve multiple therapeutic purposes depending on the desired level of isolation versus whole-plant extract usage
Data Source
AI summary
This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.